Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24690398 | 0.89 | TSHR (0.35) | TSHR | |
| SCHEMBL19069195 | 0.86 | EPHX1 (0.32) | — | |
| SCHEMBL18737456 | 0.86 | EPHX1 (0.32) | — | |
| SCHEMBL13575309 | 0.84 | SMN1; SMN2 (0.32) | L3MBTL1USP2TSHR | |
| SCHEMBL13575316 | 0.84 | SMN1; SMN2 (0.32) | L3MBTL1USP2TSHR | |
| SCHEMBL12313005 | 0.84 | SMN1; SMN2 (0.32) | L3MBTL1USP2TSHR | |
| SCHEMBL9004533 | 0.81 | MMP1 (0.35) | L3MBTL1 | |
| SCHEMBL9004535 | 0.81 | MMP1 (0.35) | L3MBTL1 | |
| SCHEMBL9004534 | 0.81 | MMP1 (0.35) | L3MBTL1 | |
| SCHEMBL20987710 | 0.79 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | L3MBTL1 2470/4885USP2 1749/4885TSHR 4378/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | L3MBTL1 3277/4885USP2 2380/4885TSHR 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.